TABLE 1.
Relationship between plasma tissue factor (TF) level and patient characteristics in a Japanese cohort with pancreatic cancer
| Factor | Low‐TF group, n = 184 | High‐TF group, n = 13 | P value | ||
|---|---|---|---|---|---|
| No. of patients (%) | Median (range) | No. of patients (%) | Median (range) | ||
| Age, y | 184 (100) | 69 (41‐85) | 13 (100) | 63 (44‐78) | .051 |
| Sex | |||||
| Male | 94 (51) | 7 (54) | |||
| Female | 90 (49) | 6 (46) | .540 | ||
| Disease status | 184 (100) | 13 (100) | |||
| Resectable | 6 (3) | 0 (0) | .047 | ||
| Locally advanced | 54 (29) | 0 (0) | |||
| Metastatic | 124 (67) | 13 (100) | |||
| ECOG‐PS | 184 (100) | 13 (100) | |||
| 0 | 76 (41) | 6 (46) | .860 | ||
| 1 | 100 (54) | 6 (46) | |||
| 2 | 7 (4) | 1 (8) | |||
| 3 | 1 (1) | 0 (0) | |||
| Hemoglobin, g/dL | 184 (100) | 12.3 (7.2‐17.1) | 13 (100) | 11.5 (8.1‐14.1) | .210 |
| Hematocrit, % | 184 (100) | 36.6 (21.3‐50.5) | 13 (100) | 34.2 (25.8‐41.3) | .220 |
| White blood cell count/μL | 184 (100) | 5700 (2500‐12 600) | 13 (100) | 7200 (4700‐13 400) | .019 |
| Platelet count, ×104/μL | 184 (100) | 21.2 (8.8‐46.3) | 13 (100) | 21.2 (11.1‐38.5) | .850 |
| Total protein, g/dL | 184 (100) | 6.7 (5.0‐8.0) | 13 (100) | 6.7 (5.8‐7.5) | .800 |
| Albumin, g/dL | 184 (100) | 3.8 (2.0‐4.7) | 13 (100) | 3.6 (2.3‐4.0) | .079 |
| Total bilirubin, mg/dL | 184 (100) | 0.7 (0.2‐6.4) | 13 (100) | 0.7 (0.4‐1.6) | .490 |
| Creatinine, mg/dL | 184 (100) | 0.65 (0.30‐1.43) | 13 (100) | 0.59 (0.45‐0.89) | .110 |
| HbA1c, % | 181 (98) | 6.5 (4.6‐13.5) | 12 (92) | 6.1 (4.7‐10.3) | .170 |
| T‐Cho, mg/dL | 179 (97) | 178 (95‐454) | 12 (92) | 188 (90‐228) | .400 |
| Triglyceride, mg/dL | 180 (98) | 99 (33‐540) | 12 (92) | 107 (61‐177) | .380 |
| HDL‐C, mg/dL | 180 (98) | 47 (12‐119) | 12 (92) | 43 (18‐73) | .350 |
| PT, % | 183 (99) | 89 (51‐122) | 13 (100) | 83 (47‐97) | .044 |
| APTT, s | 182 (99) | 29.5 (22.0‐45.0) | 13 (100) | 26.5 (22.0‐38.0) | .570 |
| Fibrinogen, mg/dL | 153 (83) | 375 (182‐627) | 11 (85) | 267 (146‐561) | .040 |
| D‐dimer, ng/mL | 149 (81) | 1.4 (0.5‐16.4) | 12 (92) | 10.2 (0.7‐31.5) | <.001 |
| CA19‐9, U/mL | 174 (95) | 1090 (2.3‐642 000) | 11 (85) | 56 061 (2.1‐8 910 300) | <.001 |
| BMI, kg/m2 | 184 (100) | 20.9 (14.9‐29.6) | 13 (100) | 20.3 (15.0‐29.8) | .610 |
| Khorana score | 184 (100) | 13 (100) | |||
| 2 | 15 (8) | 1 (8) | .900 | ||
| 3 | 160 (87) | 11 (85) | |||
| 4 | 7 (4) | 1 (8) | |||
| 5 | 2 (1) | 0 (0) | |||
| Anticancer therapy | 184 (100) | 13 (100) | |||
| GEM + nab‐PTX | 81 (44) | 7 (54) | .130 | ||
| GEM | 72 (39) | 5 (38) | |||
| FOLFIRINOX | 20 (11) | 0 (0) | |||
| Surgery | 8 (4) | 0 (0) | |||
| S‐1 | 2 (1) | 0 (0) | |||
| BSC | 1 (1) | 1 (8) | |||
Note: High‐TF group, initial plasma TF level ≥100 pg/mL; low‐TF group, initial plasma TF level <100 pg/mL.
Abbreviations: APTT, activated partial thromboplastin time; BMI, body mass index; BSC, best supportive care; CA19‐9, carbohydrate antigen 19‐9; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin combination; GEM, gemcitabine; HbA1c, hemoglobin A1c; HDL‐C, high density lipoprotein cholesterol; nab‐PTX, nab‐paclitaxel; PS, performance status; PT, prothrombin time; S‐1, oral fluoropyrimidine drug; T‐Cho, total cholesterol.